Phase 2 Trial Highlights Efficacy of Novel Urticaria Therapy

Chronic inducible urticaria (CIndU) remains a therapeutic challenge for both clinicians and patients, particularly in cases resistant to standard therapies. In a recent discussion with Dermatology Times, Mark Jackson, MD, vice president of clinical development at Evommune, shared key findings from a phase 2 clinical trial investigating EVO756, an emerging treatment candidate for refractory CIndU.

Jackson emphasized that the trial enrolled patients with long-standing, difficult-to-treat disease, many of whom had not responded to available therapies for 5 to 6 years. This refractory population provided a stringent test for evaluating the agent’s efficacy and safety.

According to Jackson, the trial demonstrated robust clinical activity. Up to 30% of patients achieved complete efficacy, while an additional 10–15% experienced partial responses. Overall, approximately 70% of participants showed some level of improvement when evaluated using the Fric test, a standard method for assessing inducible urticaria. Importantly, patients also reported reduced itching at localized sites, as measured by the numeric rating scale (NRS), further supporting the drug’s symptomatic benefit.

Beyond efficacy, safety outcomes were also favorable. Jackson noted that EVO756 maintained a tolerable safety profile, with no unexpected adverse events reported during the study period. This balance between effectiveness and safety is particularly relevant in a patient population with limited therapeutic options.

The trial’s findings suggest that EVO756 could represent a promising advancement in the management of CIndU, especially for individuals with inadequate responses to antihistamines or biologics. However, Jackson acknowledged the need for further research, including larger and longer-term studies, to confirm efficacy, durability of response, and safety outcomes across broader populations.

For clinicians, the evolving data underscores the importance of monitoring pipeline therapies and understanding how they may integrate into treatment algorithms for urticaria. If subsequent studies validate these early findings, EVO756 may provide an additional therapeutic tool for addressing the unmet needs of patients struggling with persistent, inducible urticaria.